Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection
Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection
复制标题
DOI：
10.1093/jac/dki039
复制
发表时间：
2005-04-01
影响因子：
5.2
通讯作者：
Brooks, TJG
中科院分区：
文献类型：
--
作者：
Steward, J;Piercy, T;Brooks, TJG
目的：目的比较利多卡因、加替沙星和环丙沙星对实验性类鼻疽伯克霍尔德菌感染的预防和治疗效果。方法：用1.75 × 10（6）cfu的B皮下接种BALB B/c小鼠。类鼻疽576株。分别于攻毒后6 h、7 d或12 d开始，每隔12 h口服加替沙星、阿托沙星和环丙沙星（100 mg/kg），持续14 d。对照组小鼠不接受抗生素治疗。结果：没有一种治疗方案能提供100%的保护。在攻毒后6小时开始预防最为有效，环丙沙星、加替沙星和阿托沙星42天的存活率分别为58%、75%和75%。对于攻毒后第7天开始的治疗，存活率分别为17%、11%和44%。当抗生素治疗延迟至攻毒后第12天时，存活率分别下降至21%、17%和28%。地塞米松治疗后的幸存者在42天后的挑战，复发发生在所有治疗groups.Conclusions：氟喹诺酮类药物不提供良好的暴露后保护，防止感染B。假鼻疽较新的药物阿托沙星和加替沙星在这方面并不比环丙沙星好。
Objectives: To compare the efficacy of moxifloxacin, gatifloxacin and ciprofloxacin for the post-exposure prophylaxis and treatment of experimental Burkholderia pseudomallei infection. The presence of persistent infection in treated animals and the rate of relapse following dexamethasone treatment were also investigated.Methods: BALB/c mice were inoculated subcutaneously with 1.75 x 10(6) cfu of B. pseudomallei strain 576. Gatifloxacin, moxifloxacin and ciprofloxacin (100 mg/kg) were given orally at 12 hourly intervals for 14 days starting at 6 h, 7 days or 12 days post-challenge. Control mice did not receive antibiotic therapy.Results: No regimen gave 100% protection. Prophylaxis was most effective when started 6 h post-challenge, with survival rates at 42 days for ciprofloxacin, gatifloxacin and moxifloxacin being 58%, 75% and 75%, respectively. For treatment started at day 7 post-challenge, survival rates were 17%, 11% and 44%, respectively. When antibiotic treatment was delayed until day 12 post-challenge, survival rates fell to 21%, 17% and 28%, respectively. Following dexamethasone treatment of survivors at 42 days post-challenge, relapses occurred in all treatment groups.Conclusions: Fluoroquinolones do not provide good post-exposure protection against infection with B. pseudomallei. The newer agents moxifloxacin and gatifloxacin are not significantly better than ciprofloxacin for this purpose.